Echo Therapeutics, Inc. - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - May 10, 2012

Attached files
FileFilename
EX-10.1 - AT MARKET ISSUANCE SALES AGREEMENT WITH MLV & CO. DATED MAY 9, 2012. - Echo Therapeutics, Inc.ex10-1.htm
XML - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.R17.htm
10-Q - FORM 10-Q - Echo Therapeutics, Inc.echo10q-mar312012.htm
XML - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.R8.htm
EXCEL - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - Echo Therapeutics, Inc.R9.htm
EX-32.2 - CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 - Echo Therapeutics, Inc.ex32-2.htm
EX-32.1 - CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 - Echo Therapeutics, Inc.ex32-1.htm
EX-31.2 - CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 - Echo Therapeutics, Inc.ex31-2.htm
EX-31.1 - CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 - Echo Therapeutics, Inc.ex31-1.htm
EX-5.1 - OPINION OF MORGAN LEWIS & BOCKIUS LLP - Echo Therapeutics, Inc.ex5-1.htm
v2.4.0.6
Consolidated Balance Sheets (USD $)
Mar. 31, 2012
Dec. 31, 2011
Current Assets:    
Cash and cash equivalents $ 5,910,213 $ 8,995,571
Cash restricted pursuant to a vendor letter of credit 250,000 250,000
Accounts receivable    37,065
Stock subscriptions receivable    6,667
Prepaid expenses and other current assets 317,624 274,208
Total current assets 6,477,837 9,563,511
Property and Equipment, at cost:    
Computer equipment 316,095 298,290
Office and laboratory equipment (including assets under capitalized leases) 665,372 624,817
Furniture and fixtures 186,837 186,837
Manufacturing equipment 160,435 156,435
Leasehold improvements 187,264 187,264
Property and equipment, at cost 1,516,003 1,453,643
Less-Accumulated depreciation and amortization (1,145,454) (1,135,912)
Net property and equipment (including assets under capitalized leases) 370,549 317,731
Other Assets:    
Intangible assets, net of accumulated amortization 9,625,000 9,625,000
Deposits and other assets 10,816 20,565
Total other assets 9,635,816 9,645,565
Total assets 16,484,202 19,526,807
Current Liabilities:    
Accounts payable 636,658 365,298
Deferred revenue 123,708 123,708
Current portion of notes payable and capital lease obligation, net of discounts 2,345 2,288
Derivative warrant liability 803,794 1,035,337
Accrued expenses and other liabilities 386,714 965,832
Total current liabilities 1,953,219 2,492,463
Notes Payable and capital lease obligation, net of current portion and discounts 3,280 3,888
Deferred revenue, net of current portion 30,940 61,867
Total liabilities 1,987,439 2,558,218
Convertible Preferred Stock:Series C, $0.01 par value, authorized 10,000 shares, issued and outstanding 9,974.185 shares at March 31, 2012 and December 31, 2011 100 100
Convertible Preferred Stock:Series D, $0.01 par value, authorized 3,600,000 shares, issued and outstanding 3,006,000 shares at March 31, 2012 and December 31, 2011 (preference in liquidation of $3,006,000 at March 31, 2012) 30,060 30,060
Common Stock, $0.01 par value, authorized 100,000,000 shares, issued and outstanding 38,836,022 and 38,543,944 shares at March 31, 2012 and December 31, 2011, respectively 388,363 385,442
Additional paid-in capital 98,634,017 98,116,327
Common stock subscribed for but not paid for or issued, 0 and 33,333 shares at March 31, 2012 and December 31, 2011, respectively    6,667
Accumulated deficit (84,555,777) (81,570,007)
Total stockholders' equity 14,496,763 16,968,589
Total liabilities and stockholders' equity $ 16,484,202 $ 19,526,807

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA


This web site and associated pages are not associated with, endorsed by, or sponsored by Echo Therapeutics, Inc. and has no official or unofficial affiliation with Echo Therapeutics, Inc.


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.